Resolution of the Expert Forum "New therapeutic horizons of NAFLD"

Cover Page

Cite item

Full Text

Abstract

Aim. To present the materials of the Expert Forum "New therapeutic horizons of NAFLD," held on December 19, 2023, on the updated nomenclature of fatty liver disease (FLD), its main issues of diagnosis and treatment, the burden of cardiovascular risk in FLD patients. Executive Summary of the Resolution. It is recommended that the latest update of the FLD nomenclature be considered for adaptation to the clinical practice of doctors of all therapeutic specialties. Due to the high prevalence of a combination of non-alcoholic fatty liver disease (NAFLD) and an alcoholic component in the Russian Federation, it is essential to distinguish this subgroup of patients. Numerous clinical conditions associated with NAFLD include cardiovascular disease, pre-diabetes/type 2 diabetes mellitus, polycystic ovary syndrome, obstructive sleep apnea, sarcopenic obesity, cholelithiasis, and chronic kidney disease. Once a diagnosis of NAFLD has been made, further examination of patients should be aimed at detecting the presence of fibrosis using non-invasive methods such as transient liver elastography, FibroTest, and calculation of the FIB-4 fibrosis index. The original ademethionine can be considered a universal drug in treating NAFLD due to reducing oxidative stress and correcting concomitant fatigue and asthenia.

About the authors

Oksana M. Drapkina

National Research Center for Therapy and Preventive Medicine

Email: mlivzan@yandex.ru
ORCID iD: 0000-0002-4453-8430

акад. РАН, д-р мед. наук, проф., дир. 

Russian Federation, Moscow

Anatoly I. Martynov

Russian University of Medicine

Email: mlivzan@yandex.ru
ORCID iD: 0000-0002-0783-488X

акад. РАН, д-р мед. наук, проф., проф. каф. госпитальной терапии №1 лечебного фак-та 

Russian Federation, Moscow

Gregory P. Arutyunov

Pirogov Russian National Research Medical University

Email: mlivzan@yandex.ru
ORCID iD: 0000-0002-6645-2515

чл.-кор. РАН, проф., зав. каф. пропедевтики внутренних болезней и общей физиотерапии 

Russian Federation, Moscow

Igor G. Bakulin

Mechnikov North-Western State Medical University

Email: mlivzan@yandex.ru
ORCID iD: 0000-0002-6151-2021

д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса 

Russian Federation, Saint Petersburg

Maria A. Livzan

Omsk State Medical University

Author for correspondence.
Email: mlivzan@yandex.ru
ORCID iD: 0000-0002-6581-7017

чл.-кор. РАН, проф., ректор 

Russian Federation, Omsk

Igor V. Maev

Russian University of Medicine

Email: mlivzan@yandex.ru
ORCID iD: 0000-0001-6114-564X

акад. РАН, д-р мед. наук, проф., проректор по учебной работе – первый проректор, зав. каф. пропедевтики внутренних болезней и гастроэнтерологии 

Russian Federation, Moscow

Ilia V. Egorov

Institute of Integrative Family Therapy

Email: mlivzan@yandex.ru
ORCID iD: 0000-0001-5896-429X

д-р мед. наук, проф., зав. каф. семейной медицины

Russian Federation, Moscow

References

  1. Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809-17.e28. doi: 10.1016/j.cgh.2021.12.002
  2. Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-47. doi: 10.1097/HEP.0000000000000004
  3. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-61. doi: 10.1016/S2468-1253(22)00165-0
  4. Ивашкин В.Т., Драпкина О.М., Маев И.В., и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;25(6):31-41 [Ivashkin VT, Drapkina OM, Maev IV, et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015; 25(6):31-41 (in Russian)].
  5. Евстифеева С.Е., Шальнова С.А., Куценко В.А., и др. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022;21(9):3356 [Evstifeeva SE, Shalnova SA, Kutsenko VA, et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Cardiovascular Therapy and Prevention. 2022;21(9):3356 (in Russian)]. doi: 10.15829/1728-8800-2022-3356
  6. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. doi: 10.1186/1471-230X-6-33
  7. Кролевец Т.С., Ливзан М.А. Неалкогольная жировая болезнь печени: дайджест 2021. Доказательная гастроэнтерология. 2021;10(2):27-35 [Krolevets TS, Livzan MA. Non-alcoholic fatty liver disease: digest 2021. Russian Journal of Evidence-Based Gastroenterology. 2021;10(2):27-35 (in Russian)]. doi: 10.17116/dokgastro20211002127
  8. Вахрушев Я.М., Сучкова Е.В., Лукашевич А.П. Клиническое и прогностическое значение метаболических нарушений при неалкогольной жировой болезни печени. Терапевтический архив. 2020;92(12):31-5 [Vakhrushev YaM, Suchkova EV, Lukashevich АР. Clinical and prognostic value of metabolic disorders in non-alcoholic fatty liver disease. Terapevticheskii Arkhiv (Ter Arkh). 2020;92(12):31-5 (in Russian)]. doi: 10.26442/00403660.2020.12.200444
  9. Ливзан М.А., Гаус О.В., Николаев Н.А., и др. НАЖБП: коморбидность и ассоциированные заболевания. Экспериментальная и клиническая гастроэнтерология. 2019;10(170):57-65 [Livzan MA, Gaus V, Nikolaev NA, et al. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;10(170):57-65 (in Russian)]. doi: 10.31146/1682-8658-ecg-170-10-57-65
  10. Петунина Н.А., Тельнова М.Э., Гончарова Е.В., и др. Неалкогольная жировая болезнь печени и сахарный диабет 2-го типа: общие подходы к выбору терапии. Терапевтический архив. 2022;94(10):1155-62 [Petunina NA, Telnova ME, Goncharova EV, et al. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: general approaches to the choice of therapy. Terapevticheskii Arkhiv (Ter Arkh). 2022;94(10):1155-62 (in Russian)]. doi: 10.26442/00403660.2022.10.201921
  11. Mantovani A, Zaza G, Byrne CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2018;79:64-76. doi: 10.1016/j.metabol.2017.11.003
  12. Черкащенко Н.А., Ливзан М.А., Гаус О.В., Кролевец Т.С. Неалкогольная жировая болезнь печени и желчнокаменная болезнь: случайное или закономерное сочетание? Гастроэнтерология. Хирургия. Интенсивная терапия. Consilium Medicum. 2019;3:40-4 [Cherkashchenko NA, Livzan MA, Gaus OV, Krolevets TS. Non-alcoholic fatty liver disease and cholelithiasis: a random or regular combination? Gastroenterology. Surgery. Intensive care. Consilium Medicum. 2019;3:40-4 (in Russian)]. doi: 10.26442/26583739.2019.3.190489
  13. Jaruvongvanich V, Sanguankeo A, Upala S. Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2016;61(8):2389-96. doi: 10.1007/s10620-016-4125-2
  14. Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol. 2013;19(45):8301-11. doi: 10.3748/wjg.v19.i45.8301
  15. Targher G, Lonardo A, Rossini M. Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? J Endocrinol Invest. 2015;38(8):817-25. doi: 10.1007/s40618-015-0315-6
  16. Rocha ALL, Faria LC, Guimarães TCM, et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. J Endocrinol Invest. 2017;40(12):1279-88. doi: 10.1007/s40618-017-0708-9
  17. Manzano-Nunez R, Santana-Dominguez M, Rivera-Esteban J, et al. Non-Alcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression. J Clin Med. 2023;12(3):856. doi: 10.3390/jcm12030856
  18. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012;33(10):1190-200. doi: 10.1093/eurheartj/ehr453
  19. Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589-600. doi: 10.1016/j.jhep.2016.05.013
  20. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043
  21. Alon L, Corica B, Raparelli V, et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(6):938-46. doi: 10.1093/eurjpc/zwab212
  22. Павлов Ч., Бакулин И.Г. Неалкогольный стеатогепатит: клинические особенности и принципы лечения. Врач. 2007;10:24-8 [Pavlov Ch, Bakulin IG. Non-alcoholic steatohepatitis: clinical features and treatment principles. Vrach. 2007;10:24-8 (in Russian)].
  23. Бакулин И.Г., Сандлер Ю.Г., Кейян В.А., и др. Оценка стеатоза печени с помощью неинвазивного метода: миф или реальность? Доктор.Ру. Гастроэнтерология. 2015;12(113):57-64 [Bakulin IG, Sandler YuG, Keyan VA, et al. Assessment of hepatic steatosis using a non-invasive method: myth or reality? Doctor.Ru. Gastroenterology. 2015;12(113):57-64 (in Russian)].
  24. Бакулин И.Г., Сандлер Ю.Г. Возможности применения гепатопротекторов в практике врача-терапевта. Consilium Medicum. 2010;12(8):72-6 [Bakulin IG, Sandler YG. Vozmozhnosti primeneniya gepatoprotektorov v praktike vracha-terapevta. Consilium Medicum. 2010;12(8):72-6 (in Russian)].
  25. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312
  26. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-9. doi: 10.1016/j.jhep.2020.03.039
  27. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-86. doi: 10.1097/HEP.0000000000000520
  28. Неалкогольная жировая болезнь печени у взрослых: клинические рекомендации 2022 г. Режим доступа: https://rsls.ru/files/PR2022.pdf . Ссылка активна на 19.02.24 [Nealkogol'naia zhirovaia bolezn' pecheni u vzroslykh: klinicheskie rekomendatsii 2022 g. Available at: https://rsls.ru/files/PR2022.pdf. Accessed: 19.02.2024 (in Russian)].
  29. Newton JL, Jones DE, Henderson E, et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut. 2008;57(6):807-13. doi: 10.1136/gut.2007.139303
  30. Бикбулатова Л.Ф., Кутлубаев М.А., Ахмадеева Л.Р. Шкала оценки усталости (перевод на русский язык), адаптация и оценка психометрических свойств в стационарах клиник неврологии и терапии. Медицинский вестник Башкортостана. 2012;7(1):37-42 [Bikbulatova LF, Kutlubaev MA, Akhmadeeva LR. Fatigue assessment scale (translation into Russian), adaptation and assessment of psychometric properties in inpatient neurology and therapy clinics. Medical Bulletin of Bashkortostan. 2012;7(1):37-42 (in Russian)].
  31. Younossi ZM, Paik JM, Golabi P, et al. The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005–2010 and 2017–2018. Liver Int. 2022;42(12):2646-61. doi: 10.1111/liv.15437
  32. Павлов А.И., Иволгин А.Ф., Катенко С.В., и др. Диагностика и лечение неалкогольной жировой болезни печени с сопутствующим астеническим синдромом. Терапевтический архив. 2021;93(8):890-6 [Pavlov AI, Ivolgin AF, Katenko SV, et al. Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome. Terapevticheskii Arkhiv (Ter. Arkh). 2021;93(8):890-6 (in Russian)]. doi: 10.26442/00403660.2021.08.200974
  33. Jennison E, Byrne CD. Recent advances in NAFLD: current areas of contention. Fac Rev. 2023;12:10. doi: 10.12703/r/12-10
  34. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(2):24-42 [Ivashkin VT, Mayevskaya MV, Pavlov ChS, et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):24-42 (in Russian)].
  35. Андреев Д., Маевская Е., Дичева Д., Кузнецова Е. Диетотерапия как приоритетная тактика лечения пациентов с неалкогольной жировой болезнью печени. Врач. 2017;(7):2-6 [Andreev D, Mayevskaya E, Dicheva D, Kuznetsova E. Diet of therapy as a priority treatment policy for patients with non-alcoholic fatty liver disease. Vrach. 2017;(7):2-6 (in Russian)].
  36. Hannah WN Jr, Harrison SA. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61(5):1365-74. doi: 10.1007/s10620-016-4153-y
  37. Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of ≥10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60(4):1024-30. doi: 10.1007/s10620-014-3380-3
  38. Барановский А.Ю., Райхельсон К.Л., Марченко Н.В. Применение S-аденозилметионина (Гептрала®) в терапии больных неалкогольным стеатогепатитом. Клинические перспективы гастроэнтерологии, гепатологии. 2010;1:3-10 [Baranovsky AYu, Raikhelson KL, Marchenko NV. The use of S-adenosylmethionine (Heptral®) in the treatment of patients with non-alcoholic steatohepatitis. Klinicheskie perspektivy gastroenterologii, gepatologii. 2010;1:3-10 (in Russian)].
  39. Boming L. Observation of efficacy of ademetionine for treating non-alcoholic fatty liver disease. Chinese Hepatol. 2011;16(4):350-1.
  40. Virukalpattigopalratnam MP, Singh T, Ravishankar AC. Heptral (ademetionine) in patients with intrahepatic cholestasis in chronic liver disease due to non-alcoholic liver disease: results of a multicentre observational study in India. J Indian Med Assoc. 2013;111(12):856-9.
  41. Райхельсон К.Л., Кондрашина Э.Л. Адеметионин в лечении повышенной утомляемости/слабости при заболеваниях печени: систематический обзор. Терапевтический архив. 2019;91(2):134-42 [Raikhelson KL, Kondrashina EA. Ademethionine in the treatment of fatigue in liver diseases: a systematic review. Terapevticheskii Arkhiv (Ter. Arkh). 2019;91(2):134-42 (in Russian)]. doi: 10.26442/00403660.2019.02.000130
  42. El Hadi H, Vettor R, Rossato M. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? Antioxidants (Basel). 2018;7(1). doi: 10.3390/antiox7010012
  43. Xiang Z, Chen YP, Ma KF, et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013;13:140. doi: 10.1186/1471-230X-13-140

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Variants of the course of non-alcoholic fatty liver disease.

Download (196KB)
Indexing metadata
3. Fig. 2. Modern classification of steatous (or fatty) liver disease according to the new international nomenclature (adapted from [27]).

Download (219KB)
Indexing metadata
4. Fig. 3. Results of the survey on non-alcoholic fatty liver disease and alcohol consumption, %.

Download (124KB)
Indexing metadata

Copyright (c) 2024 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies